Bill Detail

S. 3788

Congress: 119

Title

CLEAR LABELS Act

Summary

Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS Act This bill requires drugs and active pharmaceutical ingredients made available in the U.S. market to be labeled with the names and locations of their manufacturers. Specifically, a finished, packaged drug product must be labeled with the name and place of business of (1) the original manufacturer (or manufacturers) of each active pharmaceutical ingredient; (2) the original manufacturer of the finished drug product; and (3) the packer or distributor, if any. This information must be printed on the product label or made available electronically. Active pharmaceutical ingredients (which are generally sold to manufacturers and researchers, not consumers) must also be labeled with the name and place of business of their original manufacturers. Under the bill, the original manufacturer is the establishment that conducts the majority of the significant phases of manufacturing to produce the ingredient or product. The Food and Drug Administration (FDA) has discretion to determine whether a violation of these requirements constitutes misbranding and to assess a civil fine. The FDA must consider certain factors in determining whether to assess a fine, including whether the violator was notified of their noncompliance and was provided an opportunity to correct the violation. Finally, the FDA must coordinate with U.S. Customs and Border Protection to address any overlap between these requirements and existing requirements for imported drugs. These provisions take effect five years after the bill is enacted.

Sponsor

Sen. Rick Scott [R-FL]

Status

Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.

Status as of Nov 14, 2026, 4:49 PM · synced 2d ago

Introduced

2026-02-05

Data source mode: congress-gov

Bill Engagement

Lobbyists on the case

4 orgs · 59 lobbyists · 4 filings mention S. 3788 (CLEAR LABELS Act) in LDA disclosures.

These are cached disclosure mentions, not verified current representation or confirmed event attendance.

Top orgs filing
Lobbyists on this bill
+ 57 more in the full intelligence view

Limited preview · paid intelligence

Keep the intelligence current—not just this one record.

Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.

Federal Intelligence is $2,500 one-time for three months, or $9,000 for twelve months prepaid, for one named user. Full tracked federal calendar, connected organization/bill/disclosure research, and a private workspace. Fixed terms; no automatic renewal. No demo or scope email is required for standard access.

SEE A FINISHED HEALTHCARE EXAMPLE

Three days of Hill visits. Two Medicare access questions.

A separate, source-linked editorial example—not a dossier about this bill, an endorsement, or a claim of participation. The full records stay paid.

Read the finished healthcare brief →
Buy Federal Intelligence · $2,500 for 3 monthsPrefer a walkthrough first?Already a customer? Sign inGet free intelligence alerts →

After verified successful payment, access is activated within one business day and a secure setup link is emailed. Your term starts at activation. These links do not charge you or unlock records. A free alert subscription does not grant full access.